Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126413261 | 12641326 | 1 | I | 20160802 | 20160810 | 20160810 | PER | US-PFIZER INC-2016372697 | PFIZER | 0.00 | M | Y | 0.00000 | 20160810 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126413261 | 12641326 | 1 | PS | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | Oral | 100 MG, 1X/DAY | Y | 21992 | 100 | MG | PROLONGED-RELEASE TABLET | QD | |||||
| 126413261 | 12641326 | 2 | SS | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | Oral | 50 MG, 1X/DAY | Y | 21992 | 50 | MG | PROLONGED-RELEASE TABLET | QD | |||||
| 126413261 | 12641326 | 3 | SS | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | 150 MG, UNK | U | 20699 | 150 | MG | TABLET | |||||||
| 126413261 | 12641326 | 4 | C | ATORVASTATIN | ATORVASTATIN | 1 | 80 MG, UNK | 0 | 80 | MG | |||||||||
| 126413261 | 12641326 | 5 | C | OXYCODONE | OXYCODONE | 1 | 40 MG, UNK | 0 | 40 | MG | |||||||||
| 126413261 | 12641326 | 6 | C | CLONAZEPAM. | CLONAZEPAM | 1 | 1 MG, AS NEEDED | 0 | 1 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126413261 | 12641326 | 1 | Depression |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126413261 | 12641326 | Anxiety | |
| 126413261 | 12641326 | Decreased appetite | |
| 126413261 | 12641326 | Disturbance in attention | |
| 126413261 | 12641326 | Irritability | |
| 126413261 | 12641326 | Nightmare | |
| 126413261 | 12641326 | Norepinephrine decreased | |
| 126413261 | 12641326 | Paraesthesia | |
| 126413261 | 12641326 | Poor quality sleep | |
| 126413261 | 12641326 | Serum serotonin increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126413261 | 12641326 | 2 | 20160421 | 0 | ||
| 126413261 | 12641326 | 3 | 2016 | 0 |